BioMarin spends up to $490m for Alesta’s bone disease candidate
BioMarin Pharmaceutical has outlaid $490m to acquire rare disease drug developer Alesta Therapeutics, though it plans to keep only one…
19 Aug 2026
Trump expected to nominate Heidi Overton as new FDA commissioner
US President Donald Trump is expected to put forward Heidi Overton as his choice for the next commissioner of the US Food and Drug Administration (FDA), potentially marking another chapter…
19 Aug 2026
Andelyn Biosciences to develop GM2 gangliosidosis therapy
Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases. The partnership aims to…
19 Aug 2026
BeOne Medicines and partners renew Brukinsa access programme for CLL
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries…
18 Aug 2026
LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain
LEO Pharma has agreed to buy the worldwide rights to Tanabe Pharma’s drug in development for photosensitive genetic disorder treatment, bolstering the Danish company’s pipeline that has already undergone expansion…
18 Aug 2026
Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.…
18 Aug 2026
Fulcrum and Slate Medicines sign merger agreement
Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors. The…